Popular on TelAve
- WADA AWARDS - where Diamonds melt into glamour
- Rep. Gina H. Curry and Dr. Conan Tu Inspire at Kopp Foundation for Diabetes Hybrid Fundraising Gala and National Leadership Forum
- "Super Leftist", the new poetry book by Pierre Gervois
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- Cracking the Code of AGI: Phinge to Solve AGI With Netverse Patented, App-less Integrated Verified Platform & Technologies Through its Hardware
- Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets
- New Article Reveals Common Pricing Pitfalls in Flooring Projects — And How to Avoid Them
- Phinge Effect: How Billions in VC Funding Could Shift From Current Tech, AI & App-Store Developers to Fund Third-Party Platform Developers on Netverse
- $73.6 Million Multi-Year Backlog and Florida State Term Contract Drive Momentum for AI-Cybersecurity Pioneer: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
- Milwaukee Job Corps Center: Essential Workforce Training—Admissions Now Open
Similar on TelAve
- Pioneering the Future of Human-Computer Interaction Through AI-Powered Neural Input Technology: Wearable Devices Ltd. (N A S D A Q: WLDS)
- PlaceBased Media Expands Point-of-Care Advertising Inventory Across U.S. Clinic Network
- CCHR Exposes Harms Behind Today's Mental Health Awareness Campaigns
- Parkchester Oral & Maxillofacial Surgery Celebrates 450+ 5-Star Reviews
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Dominate Raleigh's Best Awards from The News & Observer
- Dr. Johnny Shanks Attends Full Arch Growth Conference 2025
- Arc Longevity Sells Out Debut Women's Creatine Gummy
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth
- Genuine Smiles Unveils New User-Friendly Website
Dr. Jeff Gelblum Provides Alzheimer's Treatment to Patients in the US and Abroad
TelAve News/10835940
AVENTURA, Fla. - TelAve -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on TelAve News
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on TelAve News
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on TelAve News
- American Star Guard Unveils a Powerful Rebrand and Expanded Security Services Throughout Nevada
- PlaceBased Media Expands Point-of-Care Advertising Inventory Across U.S. Clinic Network
- Flexible Plan Investments launches FlexDirex, a first-to-market suite of single-stock ETF strategies in the U.S
- How AI is Exposing Major Flaws in the Foundation & Structure of Technology, Hardware & the Internet & Phinge's Patented Netverse, App-less Solution
- Revenue Optics Ignites AI Revolution in Industrial Distribution
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on TelAve News
- Arnica Unveils "Arnie AI" to Secure the Future of AI-Driven Software Development
- Axiros North America Announces New CEO: Gabriel Davidov
- CCHR Exposes Harms Behind Today's Mental Health Awareness Campaigns
- Now Is the Right Time: Kaltra Highlights Its Proven Replacement Microchannel Coils
- Netverse AI to Use Less Energy: Phinge's Verified AI & Patented App-Less Platform & Hardware Will Require Less Energy, Due to its Integrated Codebase
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
0 Comments
Latest on TelAve News
- Peter Coe Verbica Stands with Rural Families and Horse Owners: "Keep Horses Classified as Livestock"
- The Mobile-First Company Raises $12M to Build Simple, Powerful Software for Small Teams
- Lick Pineapple Flavored Massage Oil Outperforming and Enticing
- Cerberus ODC in Collaboration with NVIDIA Launches All-American AI-RAN Stack, Enabling AI-Native 5G Today and Accelerating the Path to 6G
- National Compliance Firm issues Artificial Intelligence Policy Program for Mortgage Banking
- Pastor Darrell Armstrong Suspends Gubernatorial Campaign And Endorses Mikie Sherrill
- Dr. Johnny Shanks Attends Full Arch Growth Conference 2025
- Offline Asset Protection: NJTRX Implements 98 Percent Cold Storage as Industry Faces 2 Billion USD Losses
- Thousands of Smiles, Millions of Logo Views: RoarFun Brings Emotions Into Premium Retail Spaces with Formula Simulator for Immersive Brand Activation
- Qvarz LLC Expands Global Reach with High-Precision Quartz Cuvettes and Optical Components
- $300 Million Web3 Initiative and ZIGChain Partnership Power $20 Target in Noble Capital Markets Report for SEGG Media (N A S D A Q: SEGG)
- Assent Recognizes Manufacturers for Leading Supply Chain Sustainability Programs
- Arc Longevity Sells Out Debut Women's Creatine Gummy
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- Phinge, Home of Netverse, Through its Extensive Software & Hardware Patent Portfolio, Shows Founder & CEO Robert DeMaio's Vision & Innovation
- OddsTrader Reveals Early Favorites and Best Bets to Win March Madness 2026
- Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field
- Heritage at South Brunswick's Townhome Models Coming Soon!
- PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth
- Boston Industrial Solutions Unveils New and Improved Natron® UV Screen Printing Ink
